Plant Name: Acorus calamus
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.647E-10 | 4.482E-07 | CA1, CA12, CA2, CA3, CA5A, CA6, CA7, CA9, MMP12, MMP2, TP53 |
| BP | GO:0065007; biological regulation | GO:0030641; regulation of cellular pH | 3.082E-06 | 4.194E-03 | CA2, CA7, MAPK1, TP53 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 3.375E-06 | 4.313E-03 | CA2, CA7 |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 3.565E-06 | 4.313E-03 | HMGCR, MAPT, TP53 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.746E-06 | 6.120E-03 | CYP1A2, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.424E-24 | 3.101E-20 | CA1, CA12, CA14, CA2, CA3, CA5A, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.985E-19 | 2.161E-15 | CA1, CA12, CA14, CA2, CA3, CA5A, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.262E-17 | 6.868E-14 | CA1, CA12, CA2, CA3, CA5A, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 5.052E-24 | 6.365E-22 | CA12; CA1; CA3; CA2; CA5A; CA7; CA6; CA9; CA14 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.037E-05 | 6.530E-04 | MMP2; MAPK1; TP53 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 5.446E-05 | 2.287E-03 | CA2; HMGCR; CYP3A4 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 4.071E-04 | 8.801E-03 | LMNA; MAPK1; TP53 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.197E-03 | 1.662E-02 | MMP2; MAPK1; TP53 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 4.191E-04 | 8.801E-03 | MAPK1; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.563E-03 | 1.662E-02 | MAPK1; TP53 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.349E-03 | 1.662E-02 | MAPK1; TP53 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.191E-04 | 8.801E-03 | CYP1A2; CYP3A4 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 2.099E-03 | 1.662E-02 | MAPK1; TP53 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.912E-03 | 1.662E-02 | MAPK1; TP53 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 2.299E-03 | 1.662E-02 | MAPK1; MAPT; TP53 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 2.163E-03 | 1.662E-02 | MAPK1; TP53 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.675E-03 | 1.662E-02 | CYP1A2; CYP3A4 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.099E-03 | 1.662E-02 | CYP1A2; CYP3A4 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.228E-03 | 1.662E-02 | MAPK1; TP53 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 2.498E-03 | 1.662E-02 | MAPK1; TP53 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.638E-03 | 1.662E-02 | MAPK1; TP53 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.361E-03 | 1.662E-02 | CYP1A2; CYP3A4 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 3.892E-03 | 2.227E-02 | MAPK1; TP53 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 4.981E-03 | 2.510E-02 | MMP2; MAPK1 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 4.065E-03 | 2.227E-02 | MMP2; MAPK1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.638E-03 | 1.662E-02 | CYP1A2; CYP3A4 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 4.791E-03 | 2.510E-02 | MMP2; MAPK1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 7.916E-03 | 3.325E-02 | MMP2; MAPK1; TP53 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 3.315E-03 | 1.989E-02 | CYP1A2; CYP3A4 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 6.736E-03 | 3.023E-02 | MAPK1; TP53 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 6.959E-03 | 3.023E-02 | MAPK1; TP53 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 6.959E-03 | 3.023E-02 | MAPK1; TP53 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.015E-02 | 3.996E-02 | MAPK1; TP53 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 8.485E-03 | 3.449E-02 | MAPK1; TP53 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 5.240E-03 | 2.539E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| NA: NA | Cardiovascular disease | NA | HMGCR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | HMGCR |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| NA: NA | Edema | NA | CA2 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| K00-K95: Diseases of the digestive system | Chemotherapy or radiotherapy-induced mucositis | K12.3, R52, G89 | HMGCR |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | HMGCR |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | HMGCR |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; MMP12 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; HMGCR |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| C00-D49: Neoplasms | Multiple myeloma | C90 | HMGCR |
| C00-D49: Neoplasms | Cancer | C00-C96 | MMP2; CA9; CA1; MAPK1; TP53 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | HMGCR |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HMGCR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | HMGCR |
| NA: NA | Dyslipidemia | NA | HMGCR |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | HMGCR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Elevated CRP | E78.0 | HMGCR |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| A00-B99: Certain infectious and parasitic diseases | HBV infection | B16, B18.0, B18.1 | HMGCR |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| NA: NA | Hyperlipidemia | NA | HMGCR |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MMP2; CA9; MAPK1; TP53 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | HMGCR |